[1] |
VAN DE DONK N W C J, PAWLYN C, YONG K L. Multiple myeloma[J]. Lancet, 2021, 397(10272): 410-427.
doi: 10.1016/S0140-6736(21)00135-5
pmid: 33516340
|
[2] |
KOH H M, HYUN C L, JANG B G, et al. CXCR3 expression as a prognostic factor in gastric cancer: a meta-analysis[J]. Transl Cancer Res, 2021, 10(3): 1449-1456.
doi: 10.21037/tcr-20-2862
pmid: 35116470
|
[3] |
MA B, KHAZALI A, SHAO H S, et al. Expression of E-cadherin and specific CXCR3 isoforms impact each other in prostate cancer[J]. Cell Commun Signal, 2019, 17(1): 164.
doi: 10.1186/s12964-019-0489-1
pmid: 31831069
|
[4] |
GUDOWSKA-SAWCZUK M, KUDELSKI J, MROCZKO B. The role of chemokine receptor CXCR3 and its ligands in renal cell carcinoma[J]. Int J Mol Sci, 2020, 21(22): 8582.
doi: 10.3390/ijms21228582
|
[5] |
CHEN X N, HE H, XIAO Y, et al. CXCL10 produced by HPV-positive cervical cancer cells stimulates exosomal PDL1 expression by fibroblasts via CXCR3 and JAK-STAT pathways[J]. Front Oncol, 2021, 11: 629350.
doi: 10.3389/fonc.2021.629350
|
[6] |
VANDE BROEK I, VANDERKERKEN K, VAN CAMP B, et al. Extravasation and homing mechanisms in multiple myeloma[J]. Clin Exp Metastasis, 2008, 25(4): 325-334.
doi: 10.1007/s10585-007-9108-4
|
[7] |
ULLAH T R. The role of CXCR4 in multiple myeloma: cells’ journey from bone marrow to beyond[J]. J Bone Oncol, 2019, 17: 100253.
doi: 10.1016/j.jbo.2019.100253
|
[8] |
WANG Y Y, WU L L, CAI H Y, et al. YL064 directly inhibits STAT3 activity to induce apoptosis of multiple myeloma cells[J]. Cell Death Discov, 2018, 4: 44.
doi: 10.1038/s41420-018-0108-8
pmid: 30302278
|
[9] |
SOLIMANDO A G, MALERBA E, LEONE P, et al. Drug resistance in multiple myeloma: soldiers and weapons in the bone marrow niche[J]. Front Oncol, 2022, 12: 973836.
doi: 10.3389/fonc.2022.973836
|
[10] |
MAISO P, MOGOLLÓN P, OCIO E M, et al. Bone marrow mesenchymal stromal cells in multiple myeloma: their role as active contributors to myeloma progression[J]. Cancers (Basel), 2021, 13(11): 2542.
doi: 10.3390/cancers13112542
|
[11] |
PELLEGRINO A, ANTONACI F, RUSSO F, et al. CXCR3-binding chemokines in multiple myeloma[J]. Cancer Lett, 2004, 207(2): 221-227.
doi: 10.1016/j.canlet.2003.10.036
pmid: 15072832
|
[12] |
GIULIANI N, BONOMINI S, ROMAGNANI P, et al. CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival[J]. Haematologica, 2006, 91(11): 1489-1497.
pmid: 17082008
|
[13] |
LUDWIG H, WEISEL K, PETRUCCI M T, et al. Olaptesed pegol, an anti-CXCL12/SDF-1 spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a phase Ⅱa study[J]. Leukemia, 2017, 31(4): 997-1000.
doi: 10.1038/leu.2017.5
|
[14] |
WANG Y Y, WU L L, CAI H Y, et al. Sinomenine derivative YL064: a novel STAT3 inhibitor with promising anti-myeloma activity[J]. Cell Death Dis, 2018, 9: 1093.
doi: 10.1038/s41419-018-1147-z
pmid: 30361529
|
[15] |
REN Z M, LANTERMANS H, KUIL A, et al. Correction to: the CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma[J]. J Hematol Oncol, 2021, 14(1): 29.
doi: 10.1186/s13045-021-01038-w
|